Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma.
about
Cutaneous T-cell lymphoma: 2014 update on diagnosis, risk-stratification, and managementNext-generation surveillance strategies for patients with lymphomaLow absolute peripheral blood CD4+ T-cell count predicts poor prognosis in R-CHOP-treated patients with diffuse large B-cell lymphoma.A new prognostic score for elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: the prognostic role of blood monocyte and lymphocyte counts is absentOverlooking evolution: a systematic analysis of cancer relapse and therapeutic resistance research.Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era.Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapyAnalysis of prognostic factors in lymphoma patients with bone marrow involvement: a single center cohort study.Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management.Peripheral blood lymphocyte to monocyte ratio recovery from low levels at diagnosis after completion of first line therapy predicts good clinical outcomes in patients with diffuse large B-cell lymphoma.Cutaneous T-cell lymphoma: 2011 update on diagnosis, risk-stratification, and management.The B7 homologues and their receptors in hematologic malignancies.Peripheral blood T cell alterations in newly diagnosed diffuse large B cell lymphoma patients and their long-term dynamics upon rituximab-based chemoimmunotherapy.Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era.Prognostic relevance of lymphocytopenia, monocytopenia and lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience in 889 patientsPrognostic effect of peripheral blood cell counts in advanced diffuse large B-cell lymphoma treated with R-CHOP-like chemotherapy: A single institution analysis.Derangement of the T-cell repertoire in patients with B-cell non-Hodgkin's lymphoma.Elevated lactate dehydrogenase levels detected during routine follow-up do not predict relapse in patients with diffuse large B-cell lymphoma who achieve complete remission after primary treatment with rituximab, cyclophosphamide, doxorubicin, vincrCutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management.Prognostic role of neutrophil-lymphocyte ratio in multiple myeloma: a dose-response meta-analysis.Patients with diffuse large B cell lymphoma in partial response or stable disease after first-line R-CHOP: the prognostic value of the absolute lymphocyte count and impact of autologous stem cell transplantation.Lymphopenia following the completion of first-line therapy predicts early relapse in patients with diffuse large B cell lymphoma.A high LDH to absolute lymphocyte count ratio in patients with DLBCL predicts for a poor intratumoral immune response and inferior survival.Prognostic role of neutrophil-to-lymphocyte ratio in diffuse large B cell lymphoma patients: an updated dose-response meta-analysis
P2860
Q27024076-7682227B-763A-4277-9654-F2085C8D5D02Q28084956-6606FC7E-0910-4CA8-B5C3-8CF9CBAC1034Q33701858-EE8D1F5F-B4BE-4EB9-8504-AF61A2DB02ADQ33945770-5E6F83E1-57D6-4D1A-81FB-CD16BA20984EQ34085685-3E2D12F0-B2F2-4E1F-B6EA-062CE188FF60Q34882773-846EBBB9-D3A7-4D88-B5D6-485AB6484F6CQ35207251-FC60FB12-D3AE-4138-9738-C7BE517A9F64Q35959252-827635D4-D93C-4998-BA86-8A32B6BFE79EQ36470196-60DECDFB-23F9-4820-9F6F-E3B133E23776Q37746065-7257AE1D-9B10-4D21-B263-604E3EFD89A1Q37944565-B7B87537-9D3F-48F0-AD52-7372AB30DC07Q37988965-C0341B07-409B-4F1B-A49A-D348258D27ABQ38757931-FF608B1F-47CF-4996-AF49-3D8FA407954BQ39400921-8D2A9DE7-6110-409B-86FD-E32EDF6BD69FQ41870099-DEE01BF8-78F4-4250-B1EB-5B5388BFF65AQ43114005-172A1D13-ED7C-4B1C-B29E-1B1313D065EBQ43683700-63679DBF-43A8-4221-85E8-2CE4AA137D05Q47569950-90C9B94E-6C47-421E-B417-CFFD88A0CF9FQ48034709-92833D66-C3A8-4CCB-9A05-E0663AB41FDCQ48502818-739A604C-340C-43A2-8A3F-D72AA7FF86ABQ48628644-129D3255-095D-4ED9-918E-3957728CA93AQ53228301-F02A6C36-9884-4017-B604-3C1F39B2635DQ55299986-D2C19F13-EB34-4E04-9AC9-FFAAEDFE7900Q58724543-F16626C8-B176-4F08-9A95-3EB95B4A8E00
P2860
Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Lymphopenia assessed during ro ...... diffuse large B-cell lymphoma.
@en
Lymphopenia assessed during routine follow-up after immunochemotherapy
@nl
type
label
Lymphopenia assessed during ro ...... diffuse large B-cell lymphoma.
@en
Lymphopenia assessed during routine follow-up after immunochemotherapy
@nl
prefLabel
Lymphopenia assessed during ro ...... diffuse large B-cell lymphoma.
@en
Lymphopenia assessed during routine follow-up after immunochemotherapy
@nl
P2093
P2860
P356
P1433
P1476
Lymphopenia assessed during ro ...... diffuse large B-cell lymphoma.
@en
P2093
C A Thompson
D J Inwards
G S Nowakowski
I N Micallef
J P Colgan
L F Porrata
P B Johnston
S M Ansell
S N Markovic
P2860
P2888
P304
P356
10.1038/LEU.2010.108
P577
2010-05-20T00:00:00Z
P5875
P6179
1041130034